DIFFUSE LARGE B-CELL LYMPHOMA

This study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

This early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with relapsed or hard-to-treat Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma. The goal was to …

This large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …

This Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had n…

This study tested adding lenalidomide (Revlimid) to standard chemotherapy (RICE) for people with relapsed diffuse large B-cell lymphoma. The goal was to see if the combination is safe and can improve response rates, helping more patients qualify for a stem cell transplant. Only 1…

This study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take the usual strong chemotherapy. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy against another commo…

This early-phase trial tested a combination of four drugs—romidepsin, gemcitabine, dexamethasone, and cisplatin—in 21 people with peripheral T-cell or diffuse large B-cell lymphoma who had already tried other treatments. The main goal was to find a safe dose of romidepsin when ad…

This study tested the drug chidamide as a maintenance treatment for 30 people with a type of lymphoma (DLBCL) who also have hepatitis B. All participants had finished chemotherapy and their cancer was in complete remission. The goal was to see if chidamide could help keep the can…

This study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…

This early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see…

This early-phase trial tested a new treatment called BZ019, made from a patient's own immune cells modified to attack cancer. It involved 12 adults with aggressive B-cell lymphomas that had not responded to standard therapy. The main goals were to check safety and see if the trea…

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This early-phase trial tested a new cell therapy called C-CAR066 in 7 people with diffuse large B-cell lymphoma whose cancer had returned after CD19 CAR-T treatment. The therapy uses the patient's own immune cells, modified to target a different protein (CD20) on cancer cells. Th…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…

This early-phase study tested a new treatment called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The goal was to find a safe dose and see if the therapy can shrink tumors. The study is now compl…

This early-phase study tested a new cell therapy called C-CAR039 in 3 adults with B-cell non-Hodgkin's lymphoma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and CD20) on cancer cells. T…

This Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma. The study involved 270 participants and compared the combination to chemotherapy alone. The ma…

This study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that came back or didn't respond to treatment. The goal was to see if this schedule is practical and reduces side effects before patients receive CAR T-cell therapy. The approac…

This study tested whether adding lenalidomide to standard chemotherapy (R-CHOP) could help people with a fast-growing type of lymphoma called diffuse large B-cell lymphoma. The trial included 60 adults aged 18 to 70 who had not been treated before and were at medium to high risk.…

This study tested whether adding focused radiation to leftover cancer spots can improve outcomes for people with non-Hodgkin lymphoma whose tumors didn't fully respond to CAR-T cell therapy. Fourteen adults received radiation to those remaining areas. The goal was to see if this …

This early-phase trial tested a chemotherapy regimen called DA-EPOCH-R in 4 children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The drugs are given as a continuous infusion over several days, and doses are adjusted based on how the child's body handles them. The goal wa…

This early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safe…

This early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …

This completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…

This early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells.…

This study tested whether a supervised resistance training program could help lymphoma patients maintain muscle mass and physical function while undergoing chemotherapy. Forty-two adults with newly diagnosed lymphoma were randomly assigned to either the exercise program or usual …

This study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…

This study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…

This study followed 60 adults with diffuse large B-cell lymphoma or transformed lymphoma who received commercial axi-cel therapy. Researchers measured changes in memory, attention, executive function, hand strength, and quality of life using surveys and cognitive tests. The goal …

This study examined how genetic variations influence the body's ability to clear high-dose methotrexate in 20 adults with diffuse large B-cell lymphoma or central nervous system lymphoma. Researchers looked for specific gene changes linked to slower drug removal. The goal was to …

This study measured how levels of circulating tumor DNA (ctDNA) change in the hours after the first round of chemotherapy in 24 people with diffuse large B cell lymphoma. The goal was to find the best time to take blood samples for monitoring the cancer. Researchers hope that a b…

This study tested a special PET scan tracer called 18F-RGD-K5 in 21 people with lymphoma. The tracer highlights blood vessel growth (angiogenesis) in tumors. Scans were done before and after two rounds of chemotherapy to see how the tumors changed. The goal was to learn whether t…

This study looked at 60 people with diffuse large B-cell lymphoma who were starting standard chemotherapy (R-CHOP). Researchers used advanced single-cell technology to analyze tumor and blood samples over two years. The goal was to find biomarkers that could help predict how well…

This study looked at whether using telemedicine (remote doctor visits) can improve how aggressive lymphomas are managed. The main goal was to see if patients got the right amount of chemotherapy on time. 350 patients from 10 hospitals took part. The study compared telemedicine su…

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…